Comparative Pharmacology
Head-to-head clinical analysis: SARCLISA versus TECVAYLI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SARCLISA versus TECVAYLI.
SARCLISA vs TECVAYLI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isatuximab is a monoclonal antibody that binds to CD38 on multiple myeloma cells, inducing apoptosis through antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). It also inhibits CD38 enzymatic activity.
Bispecific T-cell engager antibody that binds to BCMA on multiple myeloma cells and CD3 on T-cells, leading to T-cell activation and targeted cytotoxicity.
10 mg/kg intravenously weekly for the first 8 weeks, then every 2 weeks thereafter until disease progression or unacceptable toxicity.
Subcutaneous injection: Step-up dosing schedule. First dose 0.06 mg/kg, then 0.3 mg/kg on day 4, followed by 1.5 mg/kg weekly starting day 7. Maximum single dose 1.5 mg/kg.
None Documented
None Documented
Terminal elimination half-life: 9-14 days (approx. 4 weeks to reach steady state in multiple dosing).
22.5 days (range 10–35 days) based on population pharmacokinetic analysis; supports every-2-week dosing after step-up.
Renal: ~25% unchanged; Biliary/fecal: minor, primarily metabolized via liver, with metabolites excreted in bile/feces.
Primarily catabolized to small peptides and amino acids; not expected to be excreted renally or hepatically to a significant extent.
Category C
Category C
Monoclonal Antibody, Antineoplastic
Antineoplastic